ALA arovella therapeutics limited

Ann: Appendix 4C - quarterly, page-12

  1. 3,958 Posts.
    lightbulb Created with Sketch. 492
    I dont think you can say that a CR is on the cards.

    Not only has the company stated that it has 12 months worth of cash (without ANY upfront payment of any deal being taken into account), but you need to normalise the operating expenditure!

    In the last 12 months the company has had significant one off expenses in setting up the Brisbane DC centre for Westcoast, as well as setting up the in-house lab and the work that has occurred here. These costs will not be repeated and need to be taken off any cash flow projection for the coming 12 months.

    I would expect the net operating expenditure to reduce over the coming year and no capital raising to be required as per the company's guidance.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
10.5¢
Change
0.005(5.00%)
Mkt cap ! $124.7M
Open High Low Value Volume
10.0¢ 11.0¢ 10.0¢ $130.7K 1.260M

Buyers (Bids)

No. Vol. Price($)
12 1057806 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 247604 4
View Market Depth
Last trade - 16.10pm 16/07/2025 (20 minute delay) ?
ALA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.